Must be in first or second recurrence (including this recurrence)Xx_NEWLINE_xXParticipants may not have a second, clinically active, cancer; patients with second cancers which have been treated with curative intent and/or are currently inactive are allowedXx_NEWLINE_xXActive second malignancy requiring treatment or that would interfere with assessment of response of the lymphoma per investigator’s discretionXx_NEWLINE_xXSecond malignancy currently requiring active therapy (except for hormonal/antihormonal treatment, e.g. in prostate or breast cancer).Xx_NEWLINE_xXSecond primary malignancy that requires active therapy. Adjuvant hormonal therapy is allowed.Xx_NEWLINE_xXPatients with an active second malignancy (other than non-melanoma skin cancer or cervical carcinoma in situ) are NOT eligible for participation; patients who have a history of malignancy are not considered to have a currently active malignancy if they have completed therapy and are now considered by their physician to be at < 30% risk for relapseXx_NEWLINE_xXActive second cancersXx_NEWLINE_xXSecond malignancy (solid or hematologic) within the past 3 years except locally curable cancers that have been apparently curedXx_NEWLINE_xXPhase 2 only: second malignancy within the last 3 years.Xx_NEWLINE_xXSubject who has a history of second primary cancer within the past 5 years, with the exception of:Xx_NEWLINE_xXConcurrent active second malignancy for which the subject is receiving therapy, other than non-melanomatous skin cancer or superficial transitional cell carcinomaXx_NEWLINE_xXPatients with a currently active second malignancy other than non-melanoma skin cancer. Patients are not considered to have a currently active malignancy if they have completed necessary therapy and are considered by their physician to be at <30% risk of relapse at time of assessment.Xx_NEWLINE_xXParticipants with an active second malignancyXx_NEWLINE_xXActive second malignancy.Xx_NEWLINE_xXCurrently active second primary malignancy, including hematologic malignancies (leukemia, lymphoma, multiple myeloma, etc.), other than non-melanoma skin cancers, in situ cervical cancer, and ductal or lobular carcinoma in situ of the breast; subjects are considered to have a currently active malignancy if they have completed anti-cancer therapy and have not been disease free for > 2 yearsXx_NEWLINE_xXCurrently, no active second malignancy other than non-melanoma skin cancer; note: patients are not considered to have a \current active\ malignancy if they have completed anti-cancer therapy and are considered by their physicians to have a less than 30% chance of relapseXx_NEWLINE_xXComplete second remission (CR2).Xx_NEWLINE_xXComplete second remission (CR2).Xx_NEWLINE_xXNo active, second potentially life-threatening cancerXx_NEWLINE_xXUntreated and uncontrolled second tumor in the past 2 yearsXx_NEWLINE_xXSubjects with a \currently active\ second malignancy other than non-melanoma skin or superficial urothelial cancers are not eligible; subjects are not considered to have a \currently active\ malignancy if they have completed therapy and are now considered without evidence of disease for 2 years prior to cycle 1 day 1Xx_NEWLINE_xXUntreated and uncontrolled second tumor in the past 2 yearsXx_NEWLINE_xXHave a second primary malignancy that in the judgment of the investigator or Lilly may affect the interpretation of results.Xx_NEWLINE_xXPatients with a “currently active” second malignancy other than non-melanoma skin cancers; patients are not considered to have a “currently active” malignancy if they have completed therapy and are free of disease for >= 3 yearsXx_NEWLINE_xXConcomitant second malignanciesXx_NEWLINE_xXHistory of concurrent second cancers requiring active, ongoing systemic treatment.Xx_NEWLINE_xXParticipants with an active second malignancy (other than non-melanoma skin cancer or cervical carcinoma in situ). Participants who have a history of malignancy are not considered to have an active malignancy if they have completed therapy and are considered by their treating physician to be at <= 30 percent (%) risk for relapseXx_NEWLINE_xXHave a second primary malignancy that in the judgment of the investigator and sponsor may affect the interpretation of results (Part B only)Xx_NEWLINE_xXPresence of concurrent second cancer (active, not history)Xx_NEWLINE_xXSubjects with a “currently active” second malignancy other than non-melanoma skin cancers or non-invasive bladder cancers or other in-situ or non-invasive malignancies. Subjects are not considered to have a “currently active” malignancy if they have completed therapy and are free of disease for >= 3 yearsXx_NEWLINE_xXSubjects with concomitant second malignanciesXx_NEWLINE_xXMorbidities or concurrent major illness (for example, bowel obstruction or a second active malignancy) that, in the opinion of the treating healthcare provider, would make participation in the trial problematicXx_NEWLINE_xXSecond malignancy that is currently clinically significant or required active intervention during the period of 12 months prior to Screening, except early stage non-melanoma skin cancer treated with curative intent.Xx_NEWLINE_xXSecond primary malignancy within the last 5 years, unless treated definitively and with low risk of recurrence in the judgment of the treating investigatorXx_NEWLINE_xXPatients with a history of another primary malignancy that is currently clinically significant or currently requires active intervention, other than non-melanoma skin cancer and carcinoma in situ of the cervix should not be enrolled; patients are not considered to have a “currently active” malignancy if they have completed therapy for a prior malignancy, are disease free from a prior malignancy for >= 5 yrs and are considered by their physician to be less than 30% risk of relapseXx_NEWLINE_xXActive concurrent second malignancy.Xx_NEWLINE_xXPatients with a second, clinically active, cancer; patients with second cancers which have been treated with curative intent and/or are currently inactive are allowedXx_NEWLINE_xXActive second malignancy, i.e. patient known to have potentially fatal hematologic malignancy or another solid primary tumor present for which he/she may be (but not necessarily) currently receiving treatment; patients with a history of malignancy that has been completely treated, with no evidence of that cancer currently, are permitted to enroll in the trial provided treatment was completed > 2 years prior; patients with early-stage skin cancers and prostate cancer under surveillance with non-rising prostate specific antigen (PSA) are eligibleXx_NEWLINE_xXSubjects with second malignancies requiring active systemic therapy are excluded; subjects with second malignancies not requiring active systemic therapy or pre-malignant conditions such as monoclonal B-cell lymphocytosis (MBL) or monoclonal gammopathy of undetermined significance (MGUS) may be eligibleXx_NEWLINE_xXSecond invasive malignancy requiring active treatmentXx_NEWLINE_xXMetastatic disease or currently active second malignancyXx_NEWLINE_xXSecond primary malignancyXx_NEWLINE_xXPatients with a currently active second malignancy excluding non-melanomatous skin cancer or superficial transitional cell carcinoma\r\n* Note: Patients are not considered to have a \currently active\ malignancy if they have completed all therapy and are now considered without evidence of disease for 1 yearXx_NEWLINE_xXA second primary malignancy that in the judgment of the principal investigator (PI) or designee may affect the interpretation of resultsXx_NEWLINE_xXHistologically confirmed residual ovarian cancer at time of second-look surgery; patients with cytological evidence of malignant cells in washings obtained as part of the second look procedure are eligible even if biopsies are negativeXx_NEWLINE_xXNo other active second malignancy other than non-melanoma skin cancers and in situ cervical cancers within 5 years of registration\r\n* NOTE: A second malignancy is not considered active if all treatment for that malignancy is completed and the patient has been disease-free for at least 5 years prior to registrationXx_NEWLINE_xXPatients with another active second malignancy other than non-melanoma skin cancers and biochemical relapsed prostate cancer; patients that have completed all necessary therapy and are considered to be at less than 30% risk of relapse are not considered to have an active second malignancy and are eligible for enrollmentXx_NEWLINE_xXHistory of a second malignancy, excluding non-melanoma skin cell cancer within the last three years. Subjects with second malignancies that were indolent, in situ or definitively treated may be enrolled even if less than three years have elapsed since treatment. Consult the GSK Medical Monitor if second malignancies meet the requirements specified above.Xx_NEWLINE_xXCurrently active second malignancy other than non-melanoma skin cancer or carcinoma in-situ of the cervix; patients are not considered to have a “currently active” malignancy if they have completed therapy and have no evidence of recurrence for at least 5 yearsXx_NEWLINE_xX\Currently active\ second malignancy other than non-melanoma skin cancers or non-muscle invasive transitional cell carcinoma of bladder; patients are not considered to have a \currently active\ malignancy if they have completed therapy and are now considered (by their physician) to be at less than 30% risk for relapseXx_NEWLINE_xXUntreated and uncontrolled second tumor in the past 2 yearsXx_NEWLINE_xXSecond active malignancy requiring systemic therapyXx_NEWLINE_xXSecond malignancies that require active treatment with the exception of non-melanomatous skin cancers, and/or breast or prostate cancer on endocrine therapyXx_NEWLINE_xXPatients with a “currently active” second malignancy other than non-melanoma skin cancers, non-invasive bladder cancer, “low risk” adenocarcinoma of the prostate and carcinoma in situ of the cervix; patients are not considered to have a “currently active” malignancy if they have completed therapy and are free of disease for >= 2 yearsXx_NEWLINE_xXSubjects with a “currently active” second malignancy, other than non-melanoma skin cancers are not eligibleXx_NEWLINE_xXSecond primary malignancy only if treatment would interfere with the patient’s participation in this trial in the opinion of the treating physician; clear exceptions are 1) patient had a second primary malignancy but has been treated and disease free for at least 3 years, 2) in situ carcinoma (e.g. in situ carcinoma of the cervix) and, 3) additional skin cancers that have been definitively treated by surgery and/or radiation; patients with chronic lymphocytic leukemia will be allowed if their blood counts are within acceptable hematologic parameters and if they are not currently requiring cytotoxic or biologic anticancer treatment (supportive treatment such as intravenous immunoglobulin [IVIG] is permitted)Xx_NEWLINE_xXNo currently active second malignancyXx_NEWLINE_xXHaving \currently active\ second malignancy unrelated to HL or NHL, unless they have completed anti-cancer therapy, are in complete response and are considered by their physicians to be at less than 30% risk of relapseXx_NEWLINE_xXActive second malignancy that in the opinion of the principal investigator (PI) may interfere with or be adversely affected by this treatmentXx_NEWLINE_xXThere is no evidence of the second malignancy at the time of study entryXx_NEWLINE_xXFirst or second relapse of glioblastomaXx_NEWLINE_xXPatients with a current second malignancy requiring systemic therapy, other than non-melanoma skin cancers, are not eligible; if a patient has had a prior second malignancy that is not currently requiring active treatment, the patient will be considered eligibleXx_NEWLINE_xXSecond invasive melanomaXx_NEWLINE_xXPatients with active second malignancy are allowed as long as it is determined by the treating physician that the treatment of esophageal cancer is of higher priority through proper evaluation; however patients with active stage 4, metastatic cancers, receiving other systemic therapies at the time of the esophageal cancer diagnosis, will not be eligibleXx_NEWLINE_xXSecond malignancy currently requiring active therapy, except breast or prostate cancer stable on or responding to endocrine therapy.Xx_NEWLINE_xXActive second malignancyXx_NEWLINE_xXActive second malignancyXx_NEWLINE_xXSecond active neoplasiaXx_NEWLINE_xXSecond primary malignancy, except those second primary malignancies that are not considered to be competing causes of death in the opinion of the treating investigator; examples include: in situ carcinoma of the cervix, adequately treated non-melanoma carcinoma of the skin, or other malignancy treated at least 5 years previously with no evidence of recurrenceXx_NEWLINE_xXA concurrent second active and nonstable malignancyXx_NEWLINE_xXCurrently active second malignancy other than non-melanoma skin cancersXx_NEWLINE_xXCurrently active second malignancy other than non-melanoma skin cancersXx_NEWLINE_xXPatients with a history of a second malignancy within 3 years of the baseline visit excluding cutaneous carcinomas and in-situ carcinoma.Xx_NEWLINE_xXPatients with a second malignancy requiring active treatmentXx_NEWLINE_xXAn active second malignancy or history of another malignancy within the last 5 years, with exceptions.Xx_NEWLINE_xXActive concomitant second malignancy (i.e. has required treatment in the previous 6 months)Xx_NEWLINE_xXSecond primary malignancy, only if it would affect the safety of the treatment or the subject’s ability to complete study-related proceduresXx_NEWLINE_xXSecond malignancy within the last 3 yearsXx_NEWLINE_xXSecond malignancy currently requiring active therapy, except breast or prostate cancer stable on or responding to endocrine therapy.Xx_NEWLINE_xXSecond primary invasive malignancy that has not been in remission for greater than 2 years.Xx_NEWLINE_xXConcurrent second malignancy or history of HER2 negative breast cancer within five yearsXx_NEWLINE_xXNo active second cancersXx_NEWLINE_xXActive second malignancy i.e. patient known to have potentially fatal cancer present\n             for which he/she may be (but not necessarily) currently receiving treatmentXx_NEWLINE_xXPatients diagnosed with Ewing Sarcoma as a second malignant neoplasm are not eligible if they have received chemotherapy or radiation for the treatment of their primary malignancyXx_NEWLINE_xXActive second malignancy other than non-melanoma skin cancer or cervical carcinoma in situ; (patients with history of malignancy are not considered to have a “currently active” malignancy if they have completed therapy and are now considered by their physician to be at less than 30% risk for relapse)Xx_NEWLINE_xXSecond malignancy requiring active therapyXx_NEWLINE_xXActive second malignancy other than non-melanoma skin cancer or cervical carcinoma in situ; (patients with history of malignancy are not considered to have a \currently active\ malignancy if they have completed therapy and are now considered by their physician to be at less than 30% risk for relapse)Xx_NEWLINE_xXPatients with an active second primary cancer will not be eligible; patients curatively treated for a second cancer > 5 years prior to enrollment without a recurrence are eligible; patients curatively treated for a second primary cancer within the last 5 years with a =< 5% risk of recurrence are eligible; patients with a history of curatively treated basal cell carcinoma or intraepithelial neoplasia of the uterine cervix will be allowed on studyXx_NEWLINE_xXEvidence of active second malignancyXx_NEWLINE_xXSubjects with second malignancies in addition to myeloma if the second malignancy has required therapy in the last 3 years or is not in complete remissionXx_NEWLINE_xXSECOND REGISTRATION (STEP 2)Xx_NEWLINE_xXPatients may not have a \currently active\ second malignancy other than non-melanoma skin cancers; patients are not considered to have a \currently active\ malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapseXx_NEWLINE_xXNo other active second malignancy other than non-melanoma skin cancers within 3 years of pre-registration; a second malignancy is not considered active if all treatment for that malignancy is completed and the patient has been disease-free for at least 3 years prior to pre-registrationXx_NEWLINE_xXPart B: Second-Line Colorectal CancerXx_NEWLINE_xXConcurrent active malignancy other than non-melanoma skin cancers; patients are considered to be free of active malignancy if they have completed curative therapy and have a < 30% risk of relapseXx_NEWLINE_xXCurrently active second primary malignancy.Xx_NEWLINE_xXFirst or second progression of Glioblastoma;Xx_NEWLINE_xXHistory of a concurrent or second malignancy except for those outlined in protocolXx_NEWLINE_xXAn active, second potentially life-threatening cancerXx_NEWLINE_xXPatients must not have another active second malignancy other than non-melanoma skin cancers and biochemical relapsed prostate cancer; patients that have completed all necessary therapy and are considered to be at less than 30% risk of relapse are not considered to have an active second malignancy and are eligible for enrollmentXx_NEWLINE_xXSecond malignancy other than non-melanoma skin cancers within the past 5 yearsXx_NEWLINE_xXActive second primary malignancy or history of second primary malignancy within the last 3 years, with the exception of basal cell skin cancers or carcinoma in situ that have been adequately treatedXx_NEWLINE_xXHistory of concurrent second cancers requiring active, ongoing systemic treatment.Xx_NEWLINE_xXSecond malignancy: No \currently active\ second malignancy other than non-melanoma skin cancers.Xx_NEWLINE_xXCurrently active second primary malignancy or history of malignancy less than 5 years prior to the time of study eligibility (patients with history of skin cancers excluding melanoma will be eligible for participation)Xx_NEWLINE_xXSecond malignancy within the past 5 years except:Xx_NEWLINE_xXHistory of previous or concurrent (i.e., second primary) invasive melanoma.Xx_NEWLINE_xXNo active second cancersXx_NEWLINE_xXGlioblastoma or gliosarcoma in first or second recurrence onlyXx_NEWLINE_xXPatients with a history of another primary malignancy that is currently clinically significant or currently requires active intervention, other than non-melanoma skin cancer and carcinoma in situ of the cervix should not be enrolled; patients are not considered to have a “currently active” malignancy if they have completed therapy for a prior malignancy, are disease free from a prior malignancy for >= 5 yrs and are considered by their physician to be less than 30% risk of relapseXx_NEWLINE_xXPatients with a \currently active\ second malignancy other than non-melanoma skin cancers are not eligible; patients are not considered to have a \currently active\ malignancy if they have completed all therapy and are now considered without evidence of disease for 1 yearXx_NEWLINE_xXPatients with a \currently active\ second malignancy other than non-melanoma skin cancers are not to be registered; patients are not considered to have a \currently active\ malignancy if they have completed therapy and considered by their physician to be at less than 30% risk of relapseXx_NEWLINE_xXPatients with a “currently active” second malignancy other than non-melanoma skin cancers, non-invasive bladder cancer, “low risk” adenocarcinoma of the prostate and carcinoma in situ of the cervix; patients are not considered to have a “currently active” malignancy if they have completed therapy and are free of disease for >= 2 yearsXx_NEWLINE_xXCurrently active second malignancyXx_NEWLINE_xXNo active second malignancy (except non-melanomatous skin cancer or incidental prostate cancer found on cystectomy): Active second malignancy is defined as a current need for cancer therapy or a high possibility (> 30%) of recurrence during the study. Previous contralateral breast cancer is allowable unless it meets \active\ criteria as stated above.Xx_NEWLINE_xXPatients with a currently active second malignancy requiring treatmentXx_NEWLINE_xXSubjects in second or later relapse;Xx_NEWLINE_xXCurrently active second primary malignancy, including hematologic malignancies, except for non-melanoma skin cancers, in situ cervical cancer, and ductal or lobular carcinoma in situ of the breast; subjects are considered to have a currently active malignancy if they have completed anti-cancer therapy and have not been disease free for > 2 yearsXx_NEWLINE_xXPatients may not have a \currently active\ second malignancy other that non-melanoma skin cancers; patients are not considered to have a \currently active\ malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapseXx_NEWLINE_xXSubjects with a “currently active” second malignancy, other than non-melanoma skin cancers are not eligibleXx_NEWLINE_xXCurrently active second malignancy, except non-melanoma skin cancerXx_NEWLINE_xXSecond malignancy currently requiring active therapy (except for hormonal/anti-hormonal treatment e.g. in prostate or breast cancer).Xx_NEWLINE_xXPatients with active (uncontrolled, metastatic) second malignancies are excluded.Xx_NEWLINE_xXNo currently active second malignancyXx_NEWLINE_xXCurrently active second malignancy other than non-melanoma skin cancer or carcinoma in-situ of the cervix. Patients are not considered to have a \currently active\ malignancy if they have completed therapy and have no evidence of recurrence for at least 5 years.Xx_NEWLINE_xXPatients with an active second primary malignancy or history of malignancy within 5 years of enrollment are excluded, with the exception of non-melanoma skin cancers and cervical cancer which has been treated with curative therapyXx_NEWLINE_xXA second malignancy requiring active therapyXx_NEWLINE_xXSecond primary malignancy that may affect the interpretation of resultsXx_NEWLINE_xXPatients with a \currently active\ second malignancy other than non-melanoma skin cancers are not eligible; patients are not considered to have a \currently active\ malignancy if they have completed all therapy and are now considered without evidence of disease for 1 yearXx_NEWLINE_xXPatients with an active second malignancy with the exception of non-melanoma skin cancerXx_NEWLINE_xXPatients with a “currently active” second malignancy, other than non-melanoma skin cancer or in situ carcinoma of the cervix or breast; patients are not considered to have a “currently active” malignancy if they have completed anti-cancer therapy, are considered by their physician to be at less than 30% risk of relapse and at least 2-5 years have lapsedXx_NEWLINE_xXActive second malignancy, i.e., patient known to have potentially fatal cancer present for which she may be (but not necessarily) currently receiving treatment a. Patients with a history of malignancy that has been completely treated, with no evidence of that cancer currently, are permitted to enroll in the trial provided all chemotherapy was completed >6 months prior and/or bone marrow transplant (BMT) >2 years prior to first dose of rucaparibXx_NEWLINE_xXNo currently active other (second) malignancy, other than non-melanoma skin cancers; patients are not considered to have a “currently active” malignancy if they have completed anti-cancer therapy and are considered by their physicians to be at less than 30% risk of relapseXx_NEWLINE_xXMost concurrent second malignanciesXx_NEWLINE_xXSubjects with a concurrently active second malignancy other than adequately treated nonmelanoma skin cancers or in situ cervical cancer.Xx_NEWLINE_xX“Currently active” second malignancy other than non-melanoma skin cancers; patients are not considered to have a “currently active” malignancy if they have completed therapy more than 3 years ago and are considered to have a less than 30% risk of relapse based on the enrolling investigator’s assessment and documented in the medical record; a history of prostate cancer that was identified incidentally following cystoprostatectomy or cystectomy for bladder cancer is acceptable, provided that the following criteria are met: \r\n* Stage T2N0M0 or lower \r\n* Gleason score =< 7, negative margins at surgery, and prostate specific antigen (PSA) undetectable after surgeryXx_NEWLINE_xXNo “currently active” second malignancy other than non-melanoma skin cancers; patients are not considered to have a “currently active” malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapseXx_NEWLINE_xXPatients with active second malignancy are allowed as long as it is determined that the treatment of esophageal cancer is a higher priority through proper subspecialty consultationsXx_NEWLINE_xXSecond primary malignancy (skin cancer other than melanoma allowed) that is disease free for less than 3 yearsXx_NEWLINE_xXMust have been treated with one of the following in first and/or second line:Xx_NEWLINE_xXActive or recent second malignancies unless they have undergone potentially curative therapy for that malignancy and (1) have had no evidence of that disease for 5 years, and/or (2) be deemed at low risk for recurrence (less than or equal to 20% at 5 years)Xx_NEWLINE_xXPatients with an active, or likely to become active second malignancy.Xx_NEWLINE_xXSecond malignancy currently requiring active therapy (except for hormonal/anti-hormonal treatment, eg, prostate or breast cancer).Xx_NEWLINE_xXEvidence of second malignancy, abnormal cytogenetics, or morphologic evidence of myelodysplastic syndromes (MDS)Xx_NEWLINE_xXActive second malignancy; i.e., patient known to have potentially fatal cancer present for which he/she may be (but not necessarily) currently receiving treatmentXx_NEWLINE_xXPatients with a “currently active” second malignancy other than non-melanoma skin cancers, non-invasive bladder cancer, “low risk” adenocarcinoma of the prostate and carcinoma in situ of the cervix; patients are not considered to have a “currently active” malignancy if they have completed therapy and are free of disease for >= 3 yearsXx_NEWLINE_xXHave a second primary malignancy that in the judgment of the investigator and Medical Monitor may affect the interpretation of results.Xx_NEWLINE_xXHistory of a concurrent or second malignancy, except for specified exceptions in the protocol or any other cancer that has been in complete remission for ? 5 yearsXx_NEWLINE_xXAnyone with a second malignancy expected to require cytotoxic chemotherapy or immune modulating therapy within 3 months of enrollmentXx_NEWLINE_xXHaving \currently active\ second malignancy unrelated to Hodgkin lymphoma (HL) or NHL, unless they have completed anti-cancer therapy, are in complete response and are considered by their physicians to be at less than 30% risk of relapseXx_NEWLINE_xXAny \currently active\ second malignancy, other than non-melanoma skin cancer. Patients are not considered to have a \currently active\ malignancy, if they have completed therapy and are considered by their physician to be at least less than 30% risk of relapse over next 3 months.Xx_NEWLINE_xXActive second malignancy other than non-melanoma skin cancerXx_NEWLINE_xXSecond or subsequent recurrenceXx_NEWLINE_xXHave a second primary malignancy that in the judgment of the investigator and medical monitor may affect the interpretation of results.Xx_NEWLINE_xXPatients with a \currently active\ second malignancy other than non-melanoma skin cancers are not eligible; patients are not considered to have a \currently active\ malignancy if they have completed anti-cancer therapy and are considered by their physician to be at less than 30% risk of relapseXx_NEWLINE_xXPatients with a \currently active\ second malignancy other than non-melanoma skin cancer are excluded; (patients are not considered to have a \currently active\ malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapse)Xx_NEWLINE_xXHave a second primary malignancy that, in the judgment of the investigator and sponsor, may affect the interpretation of results.Xx_NEWLINE_xXSecond malignancy currently requiring active therapy.Xx_NEWLINE_xXHave a second primary malignancy that, in the judgment of the investigator and sponsor, may affect the interpretation of results. Curatively treated nonmelanoma skin cancer or in situ carcinoma of any origin is allowed.Xx_NEWLINE_xX\Currently active\ second malignancy (other than non-melanoma skin cancer, carcinoma in situ of the cervix or prostatic intraepithelial neoplasia within 1 year). Subjects are not considered to have a \currently active\ malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapse within 1 year.Xx_NEWLINE_xXA second invasive malignancy requiring active treatmentXx_NEWLINE_xXSubject has concomitant active second malignancies unless remission was achieved at least 3 years prior to study entry and subject is no longer on therapy for the malignancy.Xx_NEWLINE_xXHistory of second primary cancer within the past 5 years, with the exception of:Xx_NEWLINE_xXSecond primary malignancyXx_NEWLINE_xXAny “currently active” second malignancy, other than non-melanoma skin cancer; patients are not considered to have a \currently active” malignancy, if they have completed therapy and are considered by their physician to be at least less than 30% risk of relapse over next yearXx_NEWLINE_xXAnyone with a second malignancy expected to require cytotoxic chemotherapy or immune modulating therapy within 3 months of enrollmentXx_NEWLINE_xXNo active second malignancyXx_NEWLINE_xXConfirmed diagnosis of relapsed/refractory AML (WHO criteria) Refractory subjects, up to second consecutive salvage . Relapsed subjects including first and second relapse.Xx_NEWLINE_xXSecond primary malignancy that has not been in remission for more than 3 yearsXx_NEWLINE_xXCurrently active other malignancy excluding controlled non-melanoma skin cancer. Patients are considered NOT to have \currently active\ malignancy if they have completed any necessary therapy and are considered by their physician to be at less than 30% risk of relapse.Xx_NEWLINE_xXActive second malignancy (except non-melanomatous skin cancer or incidental prostate cancer found on cystectomy): active secondary malignancy is defined as a current need for cancer therapy or a high possibility (>30%) of recurrence during the study.Xx_NEWLINE_xXPatients with an active second malignancy within the last 2 years with the exception of:Xx_NEWLINE_xXSecond malignancy within the past 3 years except:Xx_NEWLINE_xXHave second primary malignancy that may affect the interpretation of results.Xx_NEWLINE_xXHave a second primary malignancy that in the judgment of the investigator and sponsor may affect the interpretation of resultsXx_NEWLINE_xXActively treated for a second malignancyXx_NEWLINE_xXUntreated second malignancyXx_NEWLINE_xXKnown diagnosis of second malignancy within the past 5 yearsXx_NEWLINE_xXPatients with a second malignancy that might interfere with interpretation of the results of this studyXx_NEWLINE_xXAny history of second or third degree heart block;Xx_NEWLINE_xXPatient with serious uncontrolled concurrent medical illness including but not limited to ongoing or active infection, and \currently active\ second malignancies other than non-melanoma skin cancersXx_NEWLINE_xXSecond malignancy except for skin cancer within the last 5 yearsXx_NEWLINE_xXNo concurrent second malignancy requiring systemic therapyXx_NEWLINE_xXPatients with a \currently active\ second malignancy other than non-melanoma skin or superficial urothelial cancers are not eligible; patients are not considered to have a \currently active\ malignancy if they have completed therapy and are now considered without evidence of disease for 2 yearsXx_NEWLINE_xXHistory of concurrent second cancers requiring active, ongoing systemic treatment.Xx_NEWLINE_xXHas a second concurrent active primary malignancy such as solid tumor or lymphoma under active treatmentXx_NEWLINE_xXSecond primary invasive malignancy that has not been in remission for greater than 2 years.Xx_NEWLINE_xXParticipants with second/other active cancers requiring current treatmentXx_NEWLINE_xXSecond primary cancer which is active and requiring treatmentXx_NEWLINE_xXPatients with a “currently active” second malignancy other than non-melanoma skin cancers; patients are not considered to have a “currently active” malignancy if they have completed therapy and are free of disease for >= 3 yearsXx_NEWLINE_xX